IGC Pharma (FRA:IGS1) FCF Margin % : -820.86% (As of Dec. 2023)

View and export this data going back to 2010. Start your Free Trial

What is IGC Pharma FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. IGC Pharma's Free Cash Flow for the three months ended in Dec. 2023 was €-1.54 Mil. IGC Pharma's Revenue for the three months ended in Dec. 2023 was €0.19 Mil. Therefore, IGC Pharma's FCF Margin % for the quarter that ended in Dec. 2023 was -820.86%.

As of today, IGC Pharma's current FCF Yield % is -20.03%.

The historical rank and industry rank for IGC Pharma's FCF Margin % or its related term are showing as below:

FRA:IGS1' s FCF Margin % Range Over the Past 10 Years
Min: -2073.8 Med: -181.11 Max: -4.4
Current: -539.31

During the past 13 years, the highest FCF Margin % of IGC Pharma was -4.40%. The lowest was -2073.80%. And the median was -181.11%.

FRA:IGS1's FCF Margin % is ranked worse than
68.26% of 1046 companies
in the Biotechnology industry
Industry Median: -144.01 vs FRA:IGS1: -539.31

IGC Pharma FCF Margin % Historical Data

The historical data trend for IGC Pharma's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IGC Pharma FCF Margin % Chart

IGC Pharma Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

FCF Margin %

Get a 7-Day Free Trial

-66.25

-322.80

-1,380.50

-2,076.39

-841.36

IGC Pharma Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
FCF Margin %	Get a 7-Day Free Trial															-614.38	-1,016.77	-273.24	-574.36	-820.86

Competitive Comparison of IGC Pharma's FCF Margin %

For the Biotechnology subindustry, IGC Pharma's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

IGC Pharma's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, IGC Pharma's FCF Margin % distribution charts can be found below:

* The bar in red indicates where IGC Pharma's FCF Margin % falls into.

IGC Pharma FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

IGC Pharma's FCF Margin for the fiscal year that ended in Mar. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Mar. 2023 )	/	Revenue (A: Mar. 2023 )
	=	-7.16	/	0.851
	=	-841.36 %

IGC Pharma's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-1.535	/	0.187
	=	-820.86 %

IGC Pharma FCF Margin % Related Terms

Thank you for viewing the detailed overview of IGC Pharma's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

IGC Pharma (FRA:IGS1) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IGC Pharma Inc (FRA:IGS1) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

IGC:USA

Address

10224 Falls Road, Potomac, MD, USA, 20854

Website

https://www.igcinc.us

IGC Pharma Inc develops advanced cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease, IGC-AD1 and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles. IGC-AD1 is a low-dose tetrahydrocannabinol-based formulation that is in a 146-person Phase 2 clinical trial for agitation in dementia due to Alzheimer's. IGC also markets a wellness brand, Holief, that targets women experiencing premenstrual syndrome and menstrual cramps.

IGC Pharma (FRA:IGS1) Headlines

No Headlines